Targeting IL-4 for the Treatment of Atopic Dermatitis

被引：0

作者：

Chiricozzi, Andrea ^{[1
,2
]}

Maurelli, Martina ^{[3
]}

Peris, Ketty ^{[1
,2
]}

Girolomoni, Giampiero ^{[3
]}

机构：

[1] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, Dermatol, I-00168 Rome, Italy

[2] Univ Cattolica Sacro Cuore, Dermatol, Rome, Italy

[3] Univ Verona, Dept Med, Sect Dermatol, Verona, Italy

来源：

IMMUNOTARGETS AND THERAPY | 2020年 / 9卷

关键词：

atopic dermatitis; IL-4; inhibitor; dupilumab; pascolizumab; pitrakinra; TH2; CYTOKINES; STAPHYLOCOCCUS-AUREUS; DERMAL FIBROBLASTS; DENDRITIC CELLS; TRANSGENIC MICE; LESIONAL SKIN; UP-REGULATION; IFN-GAMMA; IN-VITRO; T-CELLS;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Atopic dermatitis (AD) is an immune-mediated inflammatory skin disease characterized by a predominant type 2 immune response. Type 2 immunity is driven by multiple cytokines, including interleukin (IL)-4 and IL-13 that are considered central to AD pathogenesis and key therapeutic targets. The dual inhibition of these two cytokines or the selective inhibition of IL-13 proved elevated efficacy in treating AD, whereas the selective inhibition of IL-4 has been poorly investigated as IL-4 inhibiting agents did not show any advance in clinical development programs. This review describes the pathogenic role of IL-4 in AD and briefly resumes the main features of compounds selectively blocking IL-4.

引用

页码：151 / 156

页数：6

共 50 条

[41] Echinochrome A Treatment Alleviates Atopic Dermatitis-like Skin Lesions in NC/Nga Mice via IL-4 and IL-13 Suppression
Yun, Hyeong Rok
Ahn, Sang Woo
Seol, Bomin
Vasileva, Elena A.
Mishchenko, Natalia P.
Fedoreyev, Sergey A.
Stonik, Valentin A.
Han, Jin
Ko, Kyung Soo
Rhee, Byoung Doo
Seol, Jung Eun
Kim, Hyoung Kyu
MARINE DRUGS, 2021, 19 (11)
[42] Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis.
Neis, Mark M.
Peters, Bettina
Dreuw, Alexandra
Wenzel, Joerg
Bieber, Thomas
Mauch, Cornelia
Krieg, Thomas
Stanzel, Sven
Heinrich, Peter C.
Merk, Hans F.
Bosio, Andreas
Baron, Jens M.
Hermanns, Heike M.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 118 (04) : 930 - 937
[43] A molecular mechanism for IL-4 suppression of loricrin transcription in epidermal keratinocytes: implication for atopic dermatitis pathogenesis
Bao, Lei
Mohan, Girish C.
Alexander, Jaime B.
Doo, Caroline
Shen, Kui
Bao, Jeremy
Chan, Lawrence S.
INNATE IMMUNITY, 2017, 23 (08) : 641 - 647
[44] Angiogenesis: The major abnormality of the keratin-14 IL-4 Transgenic mouse model of atopic dermatitis
Agha-Majzoub, R
Becker, RP
Schraufnagel, DE
Chan, LS
MICROCIRCULATION, 2005, 12 (06) : 455 - 476
[45] Association between IL-4, IL-6, IL-18 polymorphisms and atopic dermatitis risk: a meta-analysis
Yang, Yang
Wang, Qingliang
Song, Xun
Jiang, Wencheng
Tang, Suwei
Shen, Fang
Xie, Shaoqiong
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (05): : 7375 - 7386
[46] The Th2 cytokine IL-4 mediates loss of skin δγT cells in atopic dermatitis
Wang, Jocelyn
Fu, Yongyao
Kaplan, Mark H.
JOURNAL OF IMMUNOLOGY, 2019, 202 (01):
[47] SPONTANEOUS EXPRESSION OF IL-4 MESSENGER-RNA IN LYMPHOCYTES FROM CHILDREN WITH ATOPIC-DERMATITIS
TANG, MLK
KEMP, TS
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1994, 97 (03): : 491 - 498
[48] Mechanism for interferon-gamma effects on T cell IL-4 expression in atopic dermatitis.
Chan, SC
Shen, K
Gebhardt, M
Hanifin, JM
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1997, 108 (04) : 232 - 232
[49] EFFECTS OF PITYROSPORUM-OVALE AND IL-4 ON INVITRO IGE PRODUCTION IN PATIENTS WITH ATOPIC-DERMATITIS
SHIELD, S
LIEBERMAN, P
HERROD, H
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1993, 91 (01) : 245 - 245
[50] Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema
Groves, R. W.
Wilbraham, D.
Fuller, R.
Longphre, M.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S54 - S54

← 1 2 3 4 5 →